We are a global family

We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.

PVRI 2026 preliminary programme release

The preliminary programme for PVRI 2026 Dublin is here! Celebrating 20 years of progress & looking ahead with cutting-edge science on new targets, AI, and global collaboration in pulmonary hypertension. Register now and submit your abstracts today.

Find out more

PHGPS findings published

Our PHGPS has released initial findings from its adult cohort in a paper published in the ERJ Open Research. Initial findings have also identified 10 global calls to action for improving PH care, which aim to enhance equitable access to care and research opportunities, particularly across areas of geographical disparities.

NEW PVRI Digital Webinar Series

The next series of the free PVRI Digital Webinar Series will kick off 11 September 2025. The new series will alternate between 'Cutting Edge Innovation in Clinical & Experimental PH' and 'Living Legends in PH: History & Personal Perspectives' sessions.

Find out more

Join us for our Breath Beyond Borders challenge

This November, we’re coming together as one global team to shine a light on PH research and innovation during PH Awareness month through our new fundraising challenge: Breath Beyond Borders. PVRI friends across the world are taking on a personal challenge that pushes their limits, and we invite you to participate.

Find out more

Join our family

Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.

Become a member

Featured events

PVRI 2026 Dublin

28 January 2026

The preliminary programme for PVRI 2026 Dublin is out! We hope you can join us, 28 January – 1 February, as we celebrate 20 years of progress and innovation in pulmonary hypertension. This year’s programme highlights advances in PAH, CTEPH, and PH in lung disease, with sessions on emerging therapies, precision medicine, and future directions. Registration and abstract submissions remain open—secure your place today.

PVRI Community Call, September 2025

19 September 2025

A monthly Community Call to discuss the latest developments in pulmonary hypertension.

Living Legend: Lewis Rubin, University of California San Diego

9 October 2025

The 'Living Legends in PH: History and Personal Perspectives' talks will feature remarkable people who have made major contributions to the field of pulmonary hypertension, bringing their science and personal stories to the worldwide PH community. Each talk will include a junior and senior facilitator to introduce the speaker and lead the discussion.

Pulmonary Hypertension in Latin America

28 October 2025

Part of the Latin America Task Force new webinar series, this session aims to evaluate PH and differential diagnosis, and the differences in phenotype presentations in Latin America and USA / Europe.

PAH is classically described as a disease in young adults, with no comorbidities. However, recent registries showed the epidemiology has changed to older patients with comorbidities (obesity, diabetes, hypertension, and coronary heart disease). In contrast, in Latin America, registries have shown that PAH patients are younger and have fewer comorbidities, which raises the question of whether Latin American patients present with a different phenotype.

Featured learning and research

Sotatercept: New Concepts and Clinical Use

This PVRI Digital Webinar is part of the 'Cutting Edge Innovation in Clinical & Experimental PH' session. Features:

Use of Dupilumab to Treat Cutaneous Complications of Continuous Prostacyclin Infusion in Pulmonary Hypertension: A Case Report and Review of Literature

Adhesive reactions are common complications of continuous treprostinil infusions, limiting their recommended use as a treatment for severe pulmonary hypertension.

Pulmonary Hypertension Outcomes After Closure of Atrial Septal Defect in Infants With Developmental Lung Disease

Pulmonary hypertension (PHTN) in infants with developmental lung disease, such as bronchopulmonary dysplasia (BPD), chronic lung disease of infancy (CLD), or congenital diaphragmatic hernia (CDH), can be exacerbated by atrial septal shunts secondary to atrial septal defects (ASD).

Sotatercept to Wean Off Prostacyclin Infusion Therapy for Pulmonary Arterial Hypertension: A Case Report

The activin signaling inhibitor sotatercept was approved for Group 1 pulmonary arterial hypertension (PAH) based on Phase 2 and 3 clinical trials showing significant improvements in primary outcomes; reduced pulmonary vascular resistance (PVR) and increased 6-min walk distance (6MWD), respectively.

News

First descriptive findings from the PHGPS adult cohort published in ERJ Open Research

Our Pulmonary Hypertension Global Patient Survey (PHGPS), the largest survey to date to explore the perspectives of patients with PH at a global scale, has released initial findings from its adult cohort of 3,329 patients living with PH.

Initial findings from adult cohort published PHGPS

PVRI Digital Webinar Series returns this September

We’re excited to announce the relaunch of the PVRI Digital Webinar Series, beginning September 2025. This free monthly series, open to all, brings together the global PH community for keynote presentations, rich discussion, and the opportunity to learn cutting-edge new research.

Join our Breath Beyond Borders fundraising challenge this November!

This PH Awareness Month, we’re inviting you to join the global PVRI community for our very first Breath Beyond Borders challenge. Throughout November, PVRI members and friends around the world will be taking on personal challenges — walking, running, cycling, speed skating, or even playing the piano — to shine a light on PH research and innovation, and raise funds for PVRI along the way.

New Leadership for PVRI’s Innovative Drug Discovery Initiative (IDDI)

We’re thrilled to announce a new chapter in the leadership of PVRI’s Innovative Drug Discovery Initiative (IDDI). We warmly welcome industry reps, Gil Golden (UTC) and Sidra Hoffman (Gossamer Bio), to the IDDI Leadership Team. They’ll be joining Sandeep Sahay and Luke Howard, who remain on as IDDI Leaders.